ADHD Symptom Rebound and Emotional Lability With Lisdexamfetamine Dimesylate in Children Aged 6 to 12 Years
Autor: | Ann C. Childress, Valerie Arnold, Bryan Dirks, John Shepski, Ben Adeyi, Brian Scheckner, Thomas Babcock, Robert A. Lasser, Frank A. Lopez |
---|---|
Rok vydání: | 2016 |
Předmět: |
Male
Parents Pediatrics medicine.medical_specialty Dextroamphetamine Evening Emotional lability Post hoc Emotions Lisdexamfetamine Dimesylate Placebo Drug Administration Schedule Parent ratings 03 medical and health sciences 0302 clinical medicine Double-Blind Method Rating scale Developmental and Educational Psychology medicine Humans 0501 psychology and cognitive sciences Child Psychiatry Mood Disorders 05 social sciences medicine.disease Clinical Psychology Treatment Outcome Mood disorders Attention Deficit Disorder with Hyperactivity Central Nervous System Stimulants Female medicine.symptom Psychology 030217 neurology & neurosurgery 050104 developmental & child psychology |
Zdroj: | Journal of Attention Disorders. 21:52-61 |
ISSN: | 1557-1246 1087-0547 |
Popis: | Objective: To describe symptom rebound in children with ADHD treated with lisdexamfetamine dimesylate (LDX) or placebo. Method: During a 4-week, randomized, double-blind, placebo-controlled trial of LDX, parents/caregivers completed the Conners’ Parent Rating Scale–Revised: Short Form symptom rating scale throughout the day. Response, rebound, and emotional lability (EL) were assessed post hoc based on predefined criteria. Results: Most participants given LDX ( n = 207) were responders throughout the day (50.7%-55.6%) versus placebo ( n = 72; 11.1%-22.2%). A total of seven (3.4%) LDX participants showed rebound in the afternoon and/or evening versus seven (9.7%) with placebo. In both groups, most incidences of rebound occurred in the evening. EL (mean) was higher in LDX rebounders and nonresponders (range = 4.2-9.0) versus LDX responders (range = 1.3-1.6) and versus placebo rebounders (range = 0.7-1.9). Conclusion: ADHD symptom rebound occurred in few participants (3.3%) given LDX (accompanied by clinically significant EL). Overall, more participants given LDX versus placebo responded throughout the day. |
Databáze: | OpenAIRE |
Externí odkaz: |